Allergic Rhinitis Laser Treatment

• Allergic rhinitis
• Sneezing, rhinorrhea, and nasal and sinus obstruction
• Reducing symptom for sneezing, rhinorrhea, nasal itching
• Immune-mediated nasal mucosal diseases

 

1. COZING-USBN features a USB interface, enabling standalone operation without requiring connection to the main unit. It can also be linked with a computer, power bank, or adapter for usage.

2. COZING-USBN is capable of managing Allergic rhinitis, sinusitis, lowering high blood pressure, and mitigating recurring symptoms.

3. User-friendly operation makes it convenient to use.

4. Compact and portable design enhances portability.

5. Simply plug in, and the laser output initiates automatically.

The Rhinitis Therapeutic Instrument mainly adopts the special soft laser light (650nm) which can get through the nasal mucosa of the human body.This kind of laser light has a special repair function to the nasal mucosa of the rhinitis patients. The repaired nasal mucosa could secrete antibacterial material including lysozyme as normal mucosa and restart the normal cleaning function of the swinging cilia on the nasal mucosa. Quickly remediate the wounded surface through irradiating the surface of the damaged mucous membrane

Abstract

Allergic rhinitis (AR) is a widespread condition that disrupts daily life and lowers quality of life. Traditional treatments often fall short in fully alleviating symptoms, prompting the exploration of new therapies. This study aimed to assess the effectiveness and safety of low-level laser therapy (LLLT) for AR through a randomized, double-blind, placebo-controlled trial. Patients diagnosed with AR were randomly assigned to receive either LLLT or a sham treatment. The primary outcome was the change in the reflective total nasal symptom score (TNSS), while the secondary outcome was the quality of life, measured using the Rhinoconjunctivitis Quality of Life Questionnaire. Adverse events were also documented. Among the 67 randomized participants, 41 (22 in the LLLT group and 19 in the sham treatment group) were included in the efficacy analysis. The LLLT group exhibited a significantly greater improvement in TNSS compared to the sham group, indicating reduced AR symptom severity (p = 0.011) and enhanced quality of life related to nasal symptoms (p = 0.036) by the end of the treatment period. No severe adverse events were reported during the study. These findings suggest that LLLT is a safe and effective option for managing AR symptoms and improving quality of life.



Methods

Participants with perennial AR were recruited. Inclusion criteria were: (1) age over 19 years; (2) mild to moderate AR symptoms at baseline (TNSS ≤ 9), including nasal congestion, rhinorrhea, sneezing, and itching, with a confirmed positive allergy test (skin prick test or multiple allergen simultaneous test) to common perennial allergens such as dust mites, molds, insects, or animal danders within the past 12 months; (3) any gender or ethnicity; and (4) signed written informed consent. Exclusion criteria included: (1) age under 18; (2) pregnant or breastfeeding; (3) definite deviated nasal septum, sinusitis, or recent nasal surgery; (4) hypertension, diabetes, malignancy, anemia, active tuberculosis, infection, asthma, or other systemic diseases; (5) long-term use of corticosteroids or immunosuppressants; (6) hypersensitivity to laser or wounds at the laser site; (7) participation in another clinical study within 30 days; (8) inability to adhere to follow-up schedules; and (9) recent use of antihistamines, topical or systemic corticosteroids, anticholinergics, antileukotrienes, decongestants, tricyclic antidepressants, phenothiazines, non-steroidal analgesics, or other drugs deemed inappropriate by researchers.



Conclusions

This study demonstrated a significant reduction in perennial AR symptoms and improved nasal-related quality of life in patients treated with LLLT compared to those receiving sham treatment. The results indicate that LLLT could be an effective and safe therapy for controlling AR symptoms.